Literature DB >> 21203938

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

Kristelle S Brown1, Michael J Keogh, Ania M Owsianka, Richard Adair, Arvind H Patel, James N Arnold, Jonathan K Ball, Robert B Sim, Alexander W Tarr, Timothy P Hickling.   

Abstract

Mannan-binding lectin (MBL) is a soluble innate immune protein that binds to glycosylated targets. MBL acts as an opsonin and activates complement, contributing to the destruction and clearance of infecting microorganisms. Hepatitis C virus (HCV) encodes two envelope glycoproteins E1 and E2, expressed as non-covalent E1/E2 heterodimers in the viral envelope. E1 and E2 are potential ligands for MBL. Here we describe an analysis of the interaction between HCV and MBL using recombinant soluble E2 ectodomain fragment, the full-length E1/E2 heterodimer, expressed in vitro, and assess the effect of this interaction on virus entry. A binding assay using antibody capture of full length E1/E2 heterodimers was used to demonstrate calcium dependent, saturating binding of MBL to HCV glycoproteins. Competition with various saccharides further confirmed that the interaction was via the lectin domain of MBL. MBL binds to E1/E2 representing a broad range of virus genotypes. MBL was shown to neutralize the entry into Huh-7 cells of HCV pseudoparticles (HCVpp) bearing E1/E2 from a wide range of genotypes. HCVpp were neutralized to varying degrees. MBL was also shown to neutralize an authentic cell culture infectious virus, strain JFH-1 (HCVcc). Furthermore, binding of MBL to E1/E2 was able to activate the complement system via MBL-associated serine protease 2. In conclusion, MBL interacts directly with HCV glycoproteins, which are present on the surface of the virion, resulting in neutralization of HCV particles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21203938      PMCID: PMC4875281          DOI: 10.1007/s13238-010-0088-9

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  60 in total

Review 1.  The burden of hepatitis C in the United States.

Authors:  W Ray Kim
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.

Authors:  François Helle; Czeslaw Wychowski; Ngoc Vu-Dac; Kirk R Gustafson; Cécile Voisset; Jean Dubuisson
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

3.  Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets.

Authors:  Eriko Yamada; Maria Montoya; Christian G Schuettler; Timothy P Hickling; Alexander W Tarr; Alessandra Vitelli; Jean Dubuisson; Arvind H Patel; Jonathan K Ball; Persephone Borrow
Journal:  J Gen Virol       Date:  2005-09       Impact factor: 3.891

Review 4.  Mannan binding lectin and viral hepatitis.

Authors:  Kristelle S Brown; Stephen D Ryder; William L Irving; Robert B Sim; Timothy P Hickling
Journal:  Immunol Lett       Date:  2006-11-20       Impact factor: 3.685

5.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

Authors:  H Nakabayashi; K Taketa; K Miyano; T Yamane; J Sato
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

7.  Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Authors:  Reginald F Clayton; Ania Owsianka; Jim Aitken; Susan Graham; David Bhella; Arvind H Patel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure.

Authors:  L Golden-Mason; L Madrigal-Estebas; E McGrath; M J Conroy; E J Ryan; J E Hegarty; C O'Farrelly; D G Doherty
Journal:  Gut       Date:  2008-03-27       Impact factor: 23.059

9.  Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans.

Authors:  Roxana E Iacob; Irina Perdivara; Michael Przybylski; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2007-12-08       Impact factor: 3.109

10.  Simultaneous activation of complement and coagulation by MBL-associated serine protease 2.

Authors:  Anders Krarup; Russell Wallis; Julia S Presanis; Péter Gál; Robert B Sim
Journal:  PLoS One       Date:  2007-07-18       Impact factor: 3.240

View more
  27 in total

1.  Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system.

Authors:  Richard Y Wang; Patricia Bare; Valeria De Giorgi; Kentaro Matsuura; Kazi Abdus Salam; Teresa Grandinetti; Cathy Schechterly; Harvey J Alter
Journal:  Hepatology       Date:  2016-10-24       Impact factor: 17.425

2.  Characterization of cellular and humoral immune responses after IBV infection in chicken lines differing in MBL serum concentration.

Authors:  Rikke Munkholm Kjærup; Tina S Dalgaard; Liselotte R Norup; Edin Hamzic; Poul Sørensen; Helle R Juul-Madsen
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

3.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

4.  Secreted NS1 Protects Dengue Virus from Mannose-Binding Lectin-Mediated Neutralization.

Authors:  Somchai Thiemmeca; Chamaiporn Tamdet; Nuntaya Punyadee; Tanapan Prommool; Adisak Songjaeng; Sansanee Noisakran; Chunya Puttikhunt; John P Atkinson; Michael S Diamond; Alongkot Ponlawat; Panisadee Avirutnan
Journal:  J Immunol       Date:  2016-10-19       Impact factor: 5.422

5.  Relationship of serum mannose-binding lectin levels with the development of sepsis: a meta-analysis.

Authors:  Dong-Na Gao; Yu Zhang; Yan-Bo Ren; Jian Kang; Li Jiang; Zhuo Feng; Ya-Nan Qu; Qing-Hui Qi; Xuan Meng
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 6.  New hepatitis C virus drug discovery strategies and model systems.

Authors:  Snawar Hussain; Naina Barretto; Susan L Uprichard
Journal:  Expert Opin Drug Discov       Date:  2012-08-04       Impact factor: 6.098

7.  Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Authors:  Mohamed R Hamed; Richard J P Brown; Carsten Zothner; Richard A Urbanowicz; Christopher P Mason; Anders Krarup; C Patrick McClure; William L Irving; Jonathan K Ball; Mark Harris; Timothy P Hickling; Alexander W Tarr
Journal:  J Innate Immun       Date:  2014-05-15       Impact factor: 7.349

8.  Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.

Authors:  A Saeed; K Baloch; R J P Brown; R Wallis; L Chen; L Dexter; C P McClure; K Shakesheff; B J Thomson
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

Review 9.  Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies.

Authors:  Emmanuelle V LeBlanc; Youjin Kim; Chantelle J Capicciotti; Che C Colpitts
Journal:  Pathogens       Date:  2021-06-01

10.  Specific acquisition of functional CD59 but not CD46 or CD55 by hepatitis C virus.

Authors:  Asim Ejaz; Eike Steinmann; Zoltán Bánki; Sana Khalid; Susanne Lengauer; Corinne Wilhelm; Heinz Zoller; Anna Schloegl; Joerg Steinmann; Elena Grabski; Michael Kleines; Thomas Pietschmann; Heribert Stoiber
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.